June 14, 2017 09:15 AM EDT
R&D

Aldeyra slides as lead drug flunks a pri­ma­ry end­point in PhI­Ib

John Carroll

Editor & Founder

First things first.

Aldeyra’s Phase IIb study for its lead eye drug ADX-102 failed the pri­ma­ry end­point in treat­ing al­ler­gic con­junc­tivi­tis. And if you …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Zealand part­ners with Roche on its amylin ana­log in a deal worth up to $5.3B

In­sil­i­co nabs $110M Se­ries E for AI drug dis­cov­ery af­ter stalling Hong Kong IPO plans

Ono li­cens­es rare blood dis­ease drug from Io­n­is for $280M up­front

As­cle­tis’ not-so-great weight loss da­ta; Vi­vace’s $35M Se­ries D

#CROI25: Mer­ck’s trou­bled HIV drug heads to reg­u­la­tors; Vi­iV seeks longer-act­ing HIV treat­ment

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times